Researchers Identify Diagenode Kit as Industry-leading Solution for Studying Global DNA Methylation

Share Article

New benchmarking study published in PLOS ONE shows Diagenode’s MethylCap Kit as best overall methyl binding domain kit for MBD-seq.

The independent validation of the MethylCap kit presented in this new peer-reviewed article demonstrates our continued commitment and leadership in DNA methylation and epigenetics research.

Diagenode, Inc., a leading global provider of complete solutions for epigenetics research, was recently cited for having the overall best methyl binding domain (MBD)-based kit in a benchmarking study of five commercially-available MBD-based kits designed to study genome-wide DNA methylation patterns. Aberrant DNA methylation has been associated with various diseases, including most cancers, cardiovascular disease, and Alzheimer's disease, highlighting the significance of the evaluation. Additionally, recent research shows that MBD-based sequencing is the most cost-efficient method for genome wide DNA methylation profiling.

Diagenode’s MethylCap assay is based on the affinity purification of methylated DNA using a MBD protein and enables high enrichment of double-stranded DNA and differential fractionation in function of the methylated CpG density. Fractionation reduces the complexity of samples and facilitates next generation sequencing.

In the study, five MBD kits were evaluated using three cell lines in conjunction with Illumina GAIIx sequencing. Reduced representation bisulfite sequencing data (RRBS) and publicly available data were used for comparisons. Diagenode's MethylCap kit demonstrated the best overall combination of high yields, consistency, specificity, and sensitivity required for high coverage sequencing. The MethylCap kit was also implicated as the solution that would yield the highest biologically relevant data. The high sensitivity of the MethylCap kit enables capture of low CpG-density fragments which have been found to show significant biological relevance.

“The independent validation of the MethylCap kit presented in this new peer-reviewed article demonstrates our continued commitment and leadership in DNA methylation and epigenetics research,” stated Didier Allaer, CEO of Diagenode. “We continuously strive for innovation in our products to produce the industry’s best epigenetics research solutions."

More information on Diagenode’s MethylCap kit can be found at http://www.diagenode.com/en/catalog/dna-methylation-65/methylbinding-domain-protein-69/. The PLOS ONE article in which the benchmarking evaluation was published can be found at http://www.plosone.org/article/info:doi/10.1371/journal.pone.0059068. The company also offers additional DNA methylation solutions using a number of approaches including meythlated DNA immunoprecipitation and bisulfite conversion.

About Diagenode, Inc.:
Diagenode is a leading provider of complete solutions for epigenetics research. The company has developed a comprehensive approach to gain new insights into epigenetics studies, offering innovative shearing and automation instruments, reagent kits, and high quality antibodies to streamline DNA methylation, ChIP, and ChIP-seq workflows. The company’s latest innovations include a unique, full automation system, ChIP-seq kits for only 10,000 cells, and the industry’s most validated antibodies. For more information about Diagenode, please visit the company’s website at http://www.diagenode.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Didier Allaer
Diagenode, Inc.
1 862 209 4680
Email >
Follow us on
Visit website